Roivant: Phase 2 namilumab study fails in sarcoidosis; development discontinued

Roivant Sciences Ltd.

Namilumab failed to meet the primary endpoint (proportion of subjects with a Rescue Event) in chronic active pulmonary sarcoidosis.
Secondary endpoints (FVC, corticosteroid tapering, King's Sarcoidosis Questionnaire) also showed no treatment benefit.
Safety profile remained consistent with prior studies; no new safety signals emerged.
Kinevant will discontinue further development of namilumab for sarcoidosis and plans to publish study results.
Roivant CEO Matt Gline acknowledged the failure but highlighted other program successes and continued clinical risk-taking.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.